Molecular Analysis of Endoscopic Cytology Samples Supernatant in Pulmonary Nodules

Summary

Lung cancer screening is based on low dose CT scan (LDCT), a highly sensitive but poorly specific tool. Complementary specific approaches are thus strongly needed, among which cell-free DNA (cfDNA) genotyping has been proven highly specific but of low sensitivity (25 to 50% for stage I diseases) due to inconstant tumor shed. Tumor biopsy is thus often required and radial endobronchial ultrasound (rEBUS) bronchoscopy is a minimally invasive approach (\<3% complications) but of limited sensitivity in cases of nodules \< 20 mm. The investigators hypothesized that methylation analysis on cfDNA floating in supernatant derived from rEBUS specimens could improve rEBUS sensitivity

Eligibility

Inclusion Criteria:

* rEBUS bronchoscopy planned for one, two or three ≤ 20 mm nodule
* World Health Organization (WHO) Performance status 0-3
* Informed signed consent
* Patient affiliated or beneficiary of a social security scheme (Social Security or Universal Medical Coverage).

Exclusion Criteria:

* Lung cancer diagnosed before the date of the procedure
* Lung cancer strongly suspected due to mediastinal or extra thoracic lesions
* Patient under State Medical Assistance
* Patient deprived of liberty on administrative or judicial decision, or patient under guardianship, curators or safeguard of justice

Conditions3

Browse More Trials